Tirzepatide vs Retatrutide

Overview

Tirzepatide is widely discussed through GIP and GLP-1 receptors. Retatrutide adds glucagon to that conversation.

The distinction is mechanistic—useful for study design, not compound ranking.

Key differences

• Tirzepatide is commonly framed as a dual GIP and GLP-1 agonist.
• Retatrutide is commonly framed across GLP-1, GIP, and glucagon receptors.
• Neither page implies superiority, interchangeability, or clinical use.

Mechanistic differences

Tirzepatide: GIP and GLP-1 receptor engagement is the central pharmacological description in metabolic literature.

Retatrutide: Glucagon co-agonism distinguishes its receptor narrative from dual incretin framing.

Pharmacology

Tirzepatide: Pharmacokinetic detail should be read from primary literature.

Retatrutide: Pharmacokinetic detail should be read from primary literature.

Research focus

Tirzepatide: GLP-1 & metabolic: Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism…

Retatrutide: GLP-1 & metabolic: Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the high…

At a glance

Practical differentiation

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/41406444/
• pubmed.ncbi.nlm.nih.gov/38912654/
• pubmed.ncbi.nlm.nih.gov/37385275/
• pubmed.ncbi.nlm.nih.gov/39536238/
• pubmed.ncbi.nlm.nih.gov/35658024/
• pubmed.ncbi.nlm.nih.gov/40353578/
• pubmed.ncbi.nlm.nih.gov/34170647/
• pubmed.ncbi.nlm.nih.gov/39555826/

FAQ